Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.

Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Weyer C

Obesity research1 Apr 2004Cited by 124 (Europe PMC)

PMID15090634DOI10.1038/oby.2004.76PepBankPUB-15090634

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In overweight or obese insulin-treated type 2 diabetes patients, pramlintide reduced HbA1c compared with placebo.
In plain wordsIn overweight or obese patients with type 2 diabetes using insulin, pramlintide reduced HbA1c more than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseHbA1c
Study
n = 498
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
120 microg BID · 26 weeksAs given in this study (human).
Measurements
Placebo-corrected HbA1c change
−0.41%
week 26
Source sentences
Summary
Pramlintide treatment resulted in significant reductions from baseline to week 26, compared with placebo, in HbA1c and body weight (both, p < 0.0001), for placebo-corrected reductions of -0.41% and -1.8 kg, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This pooled post hoc analysis of two long-term trials included all patients who were overweight/obese at baseline (BMI > 25 kg/m2), and who were treated with either 120 microg pramlintide BID (n = 254; HbA1c 9.2%; weight, 96.1 kg) or placebo (n = 244; HbA1c 9.4%; weight, 95.0 kg). Statistical endpoi…
Report a problemFND-1509063401
02HumanRandomized controlled trialEfficacy outcome
In overweight or obese insulin-treated type 2 diabetes patients, pramlintide reduced body weight compared with placebo.
In plain wordsIn overweight or obese patients with type 2 diabetes using insulin, pramlintide reduced weight more than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBody weight
Study
n = 498
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
120 microg BID · 26 weeksAs given in this study (human).
Measurements
Placebo-corrected weight change
−1.8 kg
week 26
Source sentences
Summary
Pramlintide treatment resulted in significant reductions from baseline to week 26, compared with placebo, in HbA1c and body weight (both, p < 0.0001), for placebo-corrected reductions of -0.41% and -1.8 kg, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This pooled post hoc analysis of two long-term trials included all patients who were overweight/obese at baseline (BMI > 25 kg/m2), and who were treated with either 120 microg pramlintide BID (n = 254; HbA1c 9.2%; weight, 96.1 kg) or placebo (n = 244; HbA1c 9.4%; weight, 95.0 kg). Statistical endpoi…
Report a problemFND-1509063402
03HumanRandomized controlled trialEfficacy outcome
In overweight or obese type 2 diabetes patients, more pramlintide-treated patients achieved at least 5% weight loss than placebo-treated patients.
In plain wordsIn overweight or obese type 2 diabetes patients, more patients lost at least 5% of weight with pramlintide than placebo.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseAt least five percent weight loss
Study
n = 498
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
120 microg BID · 26 weeksAs given in this study (human).
Measurements
Weight-loss responders
9%
pramlintide
Weight-loss responders
3%
placebo
Source sentences
Summary
Approximately three times the number of patients using pramlintide experienced a > or = 5% reduction of body weight than with placebo (9% vs. 3%, p = 0.0005).
1 context sentence(design, population, supporting numbers)
Summary · context
This pooled post hoc analysis of two long-term trials included all patients who were overweight/obese at baseline (BMI > 25 kg/m2), and who were treated with either 120 microg pramlintide BID (n = 254; HbA1c 9.2%; weight, 96.1 kg) or placebo (n = 244; HbA1c 9.4%; weight, 95.0 kg). Statistical endpoi…
Report a problemFND-1509063403
04HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes patients with BMI >40 kg/m2, pramlintide reduced weight compared with placebo.
In plain wordsIn type 2 diabetes patients with BMI >40 kg/m2, pramlintide reduced weight more than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBody weight in highest BMI subgroup
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
120 microg BID · 26 weeksAs given in this study (human).
Measurements
Placebo-corrected weight change
−3.2 kg
BMI >40 kg/m2 at week 26
Source sentences
Summary
The greatest placebo-corrected reductions in weight at week 26 were observed in pramlintide-treated patients with a BMI >40 kg/m2 and in those concomitantly treated with metformin (both, p < 0.001), for placebo-corrected reductions of -3.2 kg and -2.5 kg, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This pooled post hoc analysis of two long-term trials included all patients who were overweight/obese at baseline (BMI > 25 kg/m2), and who were treated with either 120 microg pramlintide BID (n = 254; HbA1c 9.2%; weight, 96.1 kg) or placebo (n = 244; HbA1c 9.4%; weight, 95.0 kg). Statistical endpoi…
Report a problemFND-1509063405
05HumanRandomized controlled trialEfficacy outcome
In overweight or obese type 2 diabetes patients using metformin, pramlintide reduced weight compared with placebo.
In plain wordsIn overweight or obese type 2 diabetes patients using metformin, pramlintide reduced weight more than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBody weight with concomitant metformin
Study
n: not reported in source
Comparator
Placebo with concomitant metformin
Outcome group
Body weight · Metabolic and weight
Studied dose
120 microg BID · 26 weeksAs given in this study (human).
Measurements
Placebo-corrected weight change
−2.5 kg
concomitant metformin at week 26
Source sentences
Summary
The greatest placebo-corrected reductions in weight at week 26 were observed in pramlintide-treated patients with a BMI >40 kg/m2 and in those concomitantly treated with metformin (both, p < 0.001), for placebo-corrected reductions of -3.2 kg and -2.5 kg, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This pooled post hoc analysis of two long-term trials included all patients who were overweight/obese at baseline (BMI > 25 kg/m2), and who were treated with either 120 microg pramlintide BID (n = 254; HbA1c 9.2%; weight, 96.1 kg) or placebo (n = 244; HbA1c 9.4%; weight, 95.0 kg). Statistical endpoi…
Report a problemFND-1509063406

Studies that did not test the peptide alone1

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

06HumanNot a test of Pramlintide (Symlin) aloneObservational studyEfficacy outcome
In overweight or obese type 2 diabetes patients, pramlintide treatment accompanied a proportionate decrease in total daily insulin use.
In plain wordsIn overweight or obese type 2 diabetes patients, pramlintide treatment accompanied a decrease in daily insulin use.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseTotal daily insulin use
Study
n = 254
Outcome group
Glycemic control · Metabolic and weight
Measurements
Correlation
0.39 r
proportionate decrease in total daily insulin use
Source sentences
Summary
Patients using pramlintide also experienced a proportionate decrease in total daily insulin use (r = 0.39, p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
This pooled post hoc analysis of two long-term trials included all patients who were overweight/obese at baseline (BMI > 25 kg/m2), and who were treated with either 120 microg pramlintide BID (n = 254; HbA1c 9.2%; weight, 96.1 kg) or placebo (n = 244; HbA1c 9.4%; weight, 95.0 kg). Statistical endpoi…
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-1509063404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.